Nomura Asset Management Co. Ltd. Has $4.41 Million Holdings in Edwards Lifesciences Corp (EW)
Nomura Asset Management Co. Ltd. raised its stake in Edwards Lifesciences Corp (NYSE:EW) by 2.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,321 shares of the medical research company’s stock after buying an additional 830 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $4,414,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently added to or reduced their stakes in EW. Optimum Investment Advisors bought a new stake in shares of Edwards Lifesciences in the first quarter worth about $110,000. IHT Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 84.6% in the first quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock worth $126,000 after acquiring an additional 427 shares in the last quarter. Well Done LLC bought a new stake in shares of Edwards Lifesciences in the first quarter worth about $152,000. Peregrine Asset Advisers Inc. bought a new stake in shares of Edwards Lifesciences in the first quarter worth about $204,000. Finally, Boston Private Wealth LLC bought a new stake in shares of Edwards Lifesciences in the first quarter worth about $205,000. 81.53% of the stock is currently owned by hedge funds and other institutional investors.
In related news, VP Catherine M. Szyman sold 9,815 shares of the stock in a transaction that occurred on Thursday, May 24th. The stock was sold at an average price of $139.39, for a total transaction of $1,368,112.85. Following the completion of the transaction, the vice president now directly owns 20,012 shares of the company’s stock, valued at $2,789,472.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 25,000 shares of the stock in a transaction that occurred on Wednesday, June 6th. The shares were sold at an average price of $141.07, for a total value of $3,526,750.00. Following the transaction, the chief financial officer now directly owns 41,265 shares of the company’s stock, valued at $5,821,253.55. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 193,515 shares of company stock valued at $27,523,945. 1.84% of the stock is owned by corporate insiders.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.13 by $0.11. The business had revenue of $972.00 million during the quarter, compared to the consensus estimate of $968.32 million. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. Edwards Lifesciences’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the company earned $1.08 earnings per share. research analysts predict that Edwards Lifesciences Corp will post 4.66 earnings per share for the current year.
Several brokerages have issued reports on EW. SunTrust Banks lowered their price target on Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a report on Friday, August 10th. ValuEngine downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. Citigroup increased their price target on Edwards Lifesciences from $115.00 to $118.00 and gave the stock a “sell” rating in a report on Tuesday, July 31st. Guggenheim restated a “buy” rating and issued a $170.00 price target on shares of Edwards Lifesciences in a report on Friday, July 27th. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $138.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $152.45.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.